Hirotoshi Iihara

6PUBLICATIONS
19CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Autonomic nervous systemClinical pharmacy and pharmacy practice
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 05, 2026
Netupitant versus aprepitant: model-predicted neurokinin-1 receptor occupancy and implications for long-delayed nausea and vomiting prevention.

|Jul 21, 2026
Systematic review of antiemetic therapy for low emetogenic chemotherapy: comparing 5-HT3 receptor antagonists and dexamethasone.

|Aug 09, 2025
Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting.

Rudolph M Navari, Timothy Tyler, Naoki Inui

|Jun 26, 2023
Effectiveness of countermeasure for polypharmacy by multidisciplinary team review in patients with diabetes mellitus.

Shohei Nishida, Takehiro Kato, Yuichi Hayashi

|Mar 03, 2022
Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracycline/cyclophosphamide regimen (JTOP-B).

Rie Ozeki, Hirotoshi Iihara, Mototsugu Shimokawa

|Apr 03, 2021
Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial.

Chizuru Sakai, Mototsugu Shimokawa, Hirotoshi Iihara

Pageof 1

Frequent Collaborators

1 joint publications

Rie Ozeki

1 joint publications

Shohei Nishida

1 joint publications

Takehiro Kato

1 joint publications

Yuichi Hayashi